Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer - Contacts and Locations

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer

This study is currently recruiting participants.

Study NCT00286793. Last updated on November 25, 2008. Information provided by Ascenta Therapeutics

Please refer to this study by its ClinicalTrials.gov identifier: NCT00286793

Contacts


Contact: Kimberli Brill, BSN	(610) 408-0301	kbrill@ascenta.com

Contact: Lance Leopold, MD	(610) 408-0301	lleopold@ascenta.com

Locations


United States, Arkansas
		Recruiting
	Hot Springs, Arkansas, United States

United States, Florida
		Recruiting
	Fort Meyers, Florida, United States

United States, Illinois
		Recruiting
	Chicago, Illinois, United States

United States, Minnesota
		Recruiting
	Fridley, Minnesota, United States

United States, New Mexico
		Recruiting
	Albuquerque, New Mexico, United States

United States, New York
		Recruiting
	Syracuse, New York, United States

United States, North Carolina
		Recruiting
	Wilmington, North Carolina, United States

United States, Oregon
		Recruiting
	Portland, Oregon, United States

United States, South Carolina
		Recruiting
	Hilton Head Island, South Carolina, United States

United States, Tennessee
		Recruiting
	Memphis, Tennessee, United States
		Recruiting
	Nashville, Tennessee, United States
		Recruiting
	Germantown, Tennessee, United States

United States, Texas
		Recruiting
	Richardson, Texas, United States

Sponsors and Collaborators

Ascenta Therapeutics

Investigators


Study Director:	Lance Leopold, MD	Ascenta Therapeutics, Inc.